上海澳华内镜股份有限公司 章程 二〇二三年八月 | 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | | 股份增减和回购 5 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东大会 | 7 | | 第一节 | 股东 | 7 | | 第二节 | | 股东大会的一般规定 9 | | 第三节 | | 股东大会的召集 13 | | 第四节 | | 股东大会的提案与通知 15 | | 第五节 | | 股东大会的召开 16 | | 第六节 | | 股东大会的表决和决议 19 | | 第五章 | 董事会 | 23 | | 第一节 | 董事 | 23 | | 第二节 | 董事会 | 26 | | 第三节 | | 董事会专门委员会 32 | | 第四节 | | 董事会秘书 33 | | 第六章 | | 总经理及其他高级管理人员 34 | | 第七章 | 监事会 | 36 | | 第一节 | 监事 | 36 | | 第二节 | 监事会 | 37 | | 第八章 ...

一、本次计提减值准备情况概述 根据《企业会计准则》以及公司会计政策、会计估计的相关规定，为了真实、准确地 反映公司截至 2023 年 6 月 30 日的财务状况，本着谨慎性原则，公司对截至 2023 年 6 月 30 日公司及下属子公司的资产进行了减值测试，对可能发生资产减值损失的相关资产计 提减值准备。2023 年半年度计提的资产减值准备为 775.15 万元。具体情况如下表所示： 单位：万元 | 项目 | 2023 年半年度计提金额 | 备注 | | --- | --- | --- | | 信用减值损失 | 359.13 | 含应收账款坏账损失及其他应收款坏账损失 | | 资产减值损失 | 416.02 | 存货跌价损失及合同履约成本减值损失 | | 合计 | 775.15 | —— | 二、计提资产减值准备事项的具体说明 证券代码：688212 证券简称：澳华内镜 公告编号：2023-040 上海澳华内镜股份有限公司 关于2023年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海澳华 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2023-041 上海澳华内镜股份有限公司 关于变更注册资本暨修订《公司章程》的公告 公司 2022 年限制性股票激励计划首次授予部分第一个归属期归属事项已于 2023 年 6 月 5 日完成股份登记工作，归属股票数量 61.50 万股，并于 2023 年 6 月 9 日上市流通。本次限制性股票归属后，公司股本总数由 133,340,000 股增加 至 133,955,000 股 ， 注 册 资 本 由 人 民 币 133,340,000 元 增 加 至 人 民 币 133,955,000 元。 二、修订公司章程的情况 根据上述变更事项，公司拟对《公司章程》进行修订，具体修订内容如下： | | 修订前 | | 修订后 | | | | --- | --- | --- | --- | --- | --- | | 第六条 | 公司注册资本：人民币 | 13,334.00 | 第六条 | 公司注册资本：人民币 | 133,955,000 | | 万元。 | | | 元。 | | | | 第十九条 | 公司股份总数为 13,334 | 万股，均 | 第十九条 | 公 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2023-038 上海澳华内镜股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 08 月 16 日（星期三）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 09 日（星期三）至 08 月 15 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aohua.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 上海澳华内镜股份有限公司（以下简称"公司"）将于 2023 年 08 月 15 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经营成果、财务状况，公司计划 ...

Financial Performance - The company's operating revenue for 2022 was approximately CNY 445.26 million, representing a year-on-year increase of 28.30% compared to CNY 347.05 million in 2021[22]. - The net profit attributable to shareholders for 2022 was CNY 21.72 million, a decrease of 61.93% from CNY 57.04 million in 2021[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 9.69 million, down 79.69% from CNY 47.72 million in 2021[22]. - The company's cash flow from operating activities showed a net outflow of CNY 41.90 million, a significant decrease of 163.34% compared to a net inflow of CNY 66.15 million in 2021[22]. - The total assets at the end of 2022 were CNY 1,460.31 million, an increase of 8.23% from CNY 1,349.24 million at the end of 2021[24]. - The net assets attributable to shareholders at the end of 2022 were CNY 1,267.99 million, reflecting a slight increase of 1.55% from CNY 1,248.62 million at the end of 2021[24]. - The company's gross profit margin for the medical device segment was 69.73%, with a slight increase of 0.44 percentage points year-on-year[115]. - The company recorded a goodwill impairment of CNY 772.68 million due to underperformance of certain subsidiaries[104]. Research and Development - The company's R&D investment accounted for 21.68% of its operating revenue, up from 14.22% in 2021, indicating a focus on product development[23]. - The company invested a total of ¥96.54 million in R&D during the reporting period, representing a 95.62% increase compared to ¥49.35 million in the previous year[79]. - R&D expenditure accounted for 21.68% of the company's total revenue, an increase of 7.46 percentage points from 14.22% in the previous year[79]. - The company applied for 17 new invention patents and received 17 authorized invention patents during the reporting period, bringing the total to 141 applications and 39 authorized patents[78]. - The company is actively developing 3D flexible endoscopes and AI diagnostic technologies, aiming to integrate these innovations into future products to improve safety and reliability[73]. - The company has established a collaborative R&D system across multiple locations, including Shanghai, Beijing, and Munich, to enhance its global innovation capabilities[77]. - The total R&D investment for the year reached CNY 369,455,000, with CNY 96,541,794 invested in the current period and a cumulative investment of CNY 276,508,113[82]. Product Development and Innovation - The company launched a new product, AQ-300, which required significant upfront promotional expenses, contributing to increased operating costs[23]. - The AQ-300 ultra-high-definition endoscope system is positioned as a leader in the 4K field, enhancing image quality and efficiency for disease management[44]. - The company launched the AQ-300 4K flexible endoscope system, which features a resolution of 3840*2160p, enhancing the detection capability of early lesions[72]. - The company is focusing on the development of endoscopic robots for complex surgeries like ERCP and ESD, aiming to improve surgical efficiency and reduce health risks[37]. - The company launched the AQ-200 intelligent multispectral system, featuring enhanced brightness and imaging quality, along with new LED light source technology[35]. - A new product, AC-1, was introduced to cater to secondary and lower-tier hospitals, emphasizing portability and adaptability in complex examination environments[36]. - The company is developing several new products, including a 3D flexible endoscope with an expected total investment of CNY 20,000,000, of which CNY 1,706,884.77 has been invested to date[82]. Market Expansion and Sales - The company has entered developed markets such as Germany, the UK, and South Korea, leveraging its competitive advantages in the flexible endoscope sector[43]. - The company plans to continue expanding its domestic marketing efforts and launching new products, such as the AQ-300, to drive future growth[110]. - Domestic sales accounted for CNY 344.05 million, a 37.83% increase, while overseas sales were CNY 101.21 million, reflecting a 3.88% increase[115]. - The company plans to enhance its operational efficiency through digital transformation initiatives aimed at streamlining processes[170]. - The company is focusing on market expansion strategies, aiming to increase its market share in the optical instrument sector[170]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of $500 million allocated for this purpose[176]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share within the next two years[183]. Corporate Governance and Compliance - The company received a standard unqualified audit report from Rongcheng Accounting Firm[5]. - The company's board of directors was fully present at the board meeting[5]. - The company held 8 supervisory board meetings during the reporting period, ensuring compliance with legal and regulatory requirements[159]. - The company disclosed information in a timely and accurate manner, enhancing transparency for investors[159]. - The company ensured fair treatment of all shareholders, providing equal access to information[159]. - The company did not face any major issues regarding independence from its controlling shareholder[160]. - The company maintained a consistent number of shares held by key executives throughout the reporting period, with no changes[166]. Risks and Challenges - The company has detailed various risks and countermeasures in its annual report, which can be found in the section discussing operational risks[4]. - The company faces risks related to market expansion, as the industry is attracting more competitors due to its broad market potential[96]. - The company relies on imported raw materials for key components, which may face procurement restrictions due to international trade issues[98]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[9]. Future Outlook - The company plans to continue enhancing product performance and expanding marketing channels to drive future growth[23]. - The company aims to achieve international certification for its products, enhancing its competitive edge in the market[82]. - The company is committed to continuous technological innovation and market expansion to enhance its competitive edge in the medical equipment sector[34]. - The company is likely to pursue further market expansion through the establishment of new subsidiaries and partnerships in the coming years[181]. - Overall, the company remains optimistic about future growth, driven by innovation and market expansion strategies[183].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 125,486,806.49, representing a year-on-year increase of 53.77%[5] - Net profit attributable to shareholders was CNY 16,547,342.99, showing a significant increase of 385.71% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached CNY 15,924,850.71, an increase of 806.55% year-on-year[5] - Basic and diluted earnings per share were both CNY 0.12, reflecting a 300.00% increase from the previous year[6] - The company reported a net profit margin improvement due to higher revenue growth outpacing cost increases[18] - In Q1 2023, the company reported a net profit of CNY 16,470,706.22, a significant increase from CNY 3,514,845.31 in Q1 2022, representing a growth of approximately 367%[19] - The total revenue from operating activities was CNY 166,983,703.12, compared to CNY 80,083,554.25 in the same period last year, indicating an increase of about 108%[23] - The total comprehensive income for the period was CNY 16,966,143.13, significantly higher than CNY 2,115,746.27 in Q1 2022[20] Research and Development - Research and development expenses totaled CNY 31,840,842.57, which is an increase of 124.04% compared to the previous year[6] - R&D expenses accounted for 25.37% of operating revenue, up by 7.96 percentage points year-on-year[6] - Research and development expenses rose to CNY 31,840,842.57, up from CNY 14,212,067.65, reflecting a growth of approximately 124% year-over-year[19] - The company reported a gross profit margin improvement, with gross profit for Q1 2023 at ¥85,246,325.06, compared to ¥49,253,349.74 in Q1 2022[29] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,453,222,912.13, a decrease of 0.49% from the end of the previous year[6] - The equity attributable to shareholders was CNY 1,290,799,124.96, reflecting an increase of 1.80% from the previous year[6] - Total assets as of March 31, 2023, were RMB 1,453,222,912.13, slightly down from RMB 1,460,306,935.06 at the end of 2022[16] - Total liabilities decreased to RMB 148,616,953.22 from RMB 178,464,557.02, indicating a reduction in financial obligations[17] - The equity attributable to shareholders increased to RMB 1,290,799,124.96 from RMB 1,267,998,483.74, reflecting retained earnings growth[17] - The total assets as of Q1 2023 amounted to ¥1,387,286,303.71, slightly up from ¥1,383,577,101.74 in Q1 2022[28] - The total liabilities decreased to ¥141,750,735.12 from ¥157,832,148.62 year-over-year, indicating a reduction of approximately 10.2%[28] - The total equity rose to ¥1,245,535,568.59, compared to ¥1,225,744,953.12 in Q1 2022, reflecting a growth of 1.6%[28] Cash Flow and Liquidity - Cash and cash equivalents decreased to RMB 188,692,553.80 as of March 31, 2023, down from RMB 230,165,799.67 at the end of 2022, indicating a liquidity contraction[15] - Accounts receivable decreased to RMB 115,003,470.74 from RMB 127,886,313.76, showing improved collection efficiency[15] - Inventory increased to RMB 205,688,286.94 from RMB 179,805,628.12, suggesting potential stockpiling or slower sales[15] - The company experienced a net cash outflow from operating activities of CNY -30,804,180.76, slightly worse than the previous year's outflow of CNY -30,663,208.12[23] - Investment activities resulted in a net cash outflow of CNY -9,466,101.38, an improvement compared to CNY -166,951,317.74 in Q1 2022[24] - The cash and cash equivalents at the end of Q1 2023 stood at CNY 188,691,553.80, down from CNY 568,605,733.92 at the end of Q1 2022[24] - Cash inflow from investment activities totaled $177,448,905.09, an increase from $151,830,650.92 in the previous year, representing a growth of approximately 16.9%[32] - Cash outflow for investment activities was $220,841,399.31, up from $208,778,775.46, indicating an increase of about 5.1%[32] - The net increase in cash and cash equivalents was -$59,702,902.97, compared to -$83,043,374.68 in the previous year, showing a reduction in cash outflow by approximately 28.1%[32] - The ending balance of cash and cash equivalents was $124,439,404.14, down from $209,004,152.12, reflecting a decrease of about 40.4% year-over-year[32] Future Outlook - The company attributed the revenue growth to enhanced market promotion and increased sales of the new product AQ300[8] - Future outlook includes potential market expansion and new product development initiatives to sustain growth momentum[18] - The company plans to continue expanding its market presence and investing in new product development to sustain growth momentum[29] Accounting and Standards - The company is implementing new accounting standards starting in 2023, which may affect the financial statements[32]

证券代码：688212 证券简称：澳华内镜 公告编号：2023-017 上海澳华内镜股份有限公司 关于参加 2022 年度医疗器械专场集体业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 4 月 28 日（星期五）9:00-11:00 会议召开方式：视频和线上文字互动 视 频 和 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （http://roadshow.sseinfo.com/） 投资者可于 2023 年 4 月 27 日（星期四）16:00 前通过邮件、电话、传 真等形式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投 资者普遍关注的问题进行回答。 上海澳华内镜股份有限公司 （以下简称"公司"）将于 2023 年 4 月 25 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年 度经营成果、财务状况、发展理念，公司参与了由上交所主办的 2022 年度医 疗器械专场 ...

证券代码： 688212 证券简称：澳华内镜 编号：2022-007 上海澳华内镜股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------|----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | 投资者关系 | □媒体采访 □业绩说明会 | | ...

证券代码： 688212 证券简称：澳华内镜 编号：2022-008 上海澳华内镜股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 \n活动类别 | □特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n 现场参观 □一对一沟通 \n 券商策略会 | 其他_（电话会） | | 参与单位及 人员 | 见附件 | | | 时间 2022 | 年 6 月 | | | 地点 | ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：688212 证券简称：澳华内镜 上海澳华内镜股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期比 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|---------------------------|----------------|-------------------------------| ...